risperidone oral tablets
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Anxiety Disorders
Conditions
Anxiety Disorders
Trial Timeline
— → Jun 1, 2005
NCT ID
NCT00086112About risperidone oral tablets
risperidone oral tablets is a phase 3 stage product being developed by Johnson & Johnson for Anxiety Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT00086112. Target conditions include Anxiety Disorders.
What happened to similar drugs?
7 of 20 similar drugs in Anxiety Disorders were approved
Approved (7) Terminated (2) Active (12)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00086112 | Phase 3 | Completed |
Competing Products
20 competing products in Anxiety Disorders